里昂發表研究報告指，信達生物(01801.HK)2024財年首季產品銷售額按年增長60%，表現超出預期。加上在近月創新藥政策的推動下，該行對公司未來數季的銷售前景仍充滿信心。里昂因而將信達生物的目標價由57.5元上調至58.1元，維持「買入」評級。(js/cy)
~
《大行》里昂升信達生物(01801.HK)目標價至58.1元 首季業績強勁
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.